OBJECTIVES: To determine the efficacy and safety of different antipsychotic drugs in the management of @entity1 diagnosed with @entity161 in the acute phase. To formulate evidence-based recommendations on the antipsychotic (AP) drug management strategies for the treatment of the adult diagnosed with @entity161 in the acute phase. METHOD: Clinical practice guidelines were prepared, using the guidelines of the Methodology Guide of the Ministry of Health and Social Protection, in order to identify, synthesise, and evaluate the evidence and formulate recommendations as regards the management and follow-up of adult @entity1 diagnosed with @entity161 . The evidence of the NICE 82 guideline was adopted and updated, which answered the question on the management of the acute phase of adults with a diagnosis of @entity161 . The evidence and its level were presented to the Guideline Development Group (GDG) in order to formulate recommendations following the methodology proposed by the GRADE approach. RESULTS: @entity1088 , @entity1037 , @entity1090 , @entity1280 , @entity14867 , @entity7302 , @entity1767 , @entity1089 , and @entity1770 were more effective than placebo for the majority of @entity716 and the abandonment of treatment, but @entity15177 was not. @entity7302 , @entity1090 , @entity1089 , @entity1088 , and @entity1037 showed significant increases in weight compared to placebo. @entity1767 , @entity1090 , @entity1280 , and @entity7302 had a higher risk of extrapyramidal symptoms than placebo. There was a significant risk of sedation or drowsiness with, @entity1090 , @entity1767 , @entity1280 , @entity1089 , @entity1037 , and @entity1088 in the comparisons with placebo. Of the results of the comparisons between AP, it was shown that @entity1088 and @entity7302 had a clinically significant effect compared to @entity1767 and @entity1089 , respectively. @entity1037 and @entity1090 had a lower risk of abandoning the treatment in general, and due to adverse reactions in two comparisons of each one, @entity1767 was the drug with more risk of abandoning due to adverse effects, followed by @entity1088 . @entity14867 , @entity1767 and @entity1280 had favourable results as regards weight increase in several comparisons. @entity1770 and @entity7302 obtained a higher number of favourable results as regards sedation, and all the atypical drugs (except @entity7302 ) had a lower risk than the use of anti- @entity191 drugs. Of the evidence from observational studies, it was found that, in subjects with risk factors for @entity6 , such as age, @entity101 , and dyslipidaemia, the initial treatment and current treatment with @entity1037 , as well as current treatment with @entity1088 , may promote the development of this disease. CONCLUSION: Although it is imperative to prescribe an antipsychotic for treatment of the acute phase, the selection of the drug depends on the particular clinical condition of each @entity1 and their collateral effects profile.

[Antipsychotic Treatment of the Adult @entity1 in the Acute Phase of XXXX ].

@entity1 :: ('9606', 'Species') :: ['patient', 'patients'] @entity1088 :: ('MESH:D003024', 'Chemical') :: ['clozapine', 'Clozapine'] @entity7302 :: ('MESH:C079150', 'Chemical') :: ['paliperidone', 'Paliperidone'] @entity15177 :: ('MESH:C522667', 'Chemical') :: ['asenapine'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity1280 :: ('MESH:C092292', 'Chemical') :: ['ziprasidone'] @entity191 :: ('MESH:D010300', 'Disease') :: ['parkinsonian'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia'] @entity716 :: ('MESH:D011605', 'Disease') :: ['psychotic symptoms'] @entity1767 :: ('MESH:D006220', 'Chemical') :: ['haloperidol', 'Haloperidol'] @entity14867 :: ('MESH:C012052', 'Chemical') :: ['Amisulpride', 'amisulpride'] @entity1037 :: ('MESH:C076029', 'Chemical') :: ['olanzapine', 'Olanzapine'] @entity1770 :: ('MESH:C094645', 'Chemical') :: ['aripiprazole', 'Aripiprazole'] @entity1089 :: ('MESH:C069541', 'Chemical') :: ['quetiapine'] @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone']
@entity161 :: (MESH:D012559,Disease) :: ['Schizophrenia']
